A new report in the New York Times about Bayer Healthcare’s bestselling oral contraceptive Yaz brings to light some serious ethical questions surrounding the company’s testing and marketing of what some studies suggest is a potentially dangerous drug for many women.
Yaz and Yasmin lawsuits filed against Bayer Healthcare in Pennsylvania state courts were consolidated into a mass tort last week by Philadelphia Court of Common Pleas judge Sandra Mazer Moss, who appointed 3 Pennsylvania attorneys to serve as liaison counsel for the plaintiffs.
The U.S. Food and Drug Administration has admonished German drug manufacturer Bayer for failing to test a vital ingredient used in Yaz and other birth control drugs according to American standards.
